massarray system (agena bioscience)
96
Structured Review
agena bioscience
massarray system
Massarray System, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 2219 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray-system-1/Methylation/pm30940696-99-1-3
Average 96 stars, based on 2219 article reviews
Massarray System, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 2219 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray-system-1/Methylation/pm30940696-99-1-3
Average 96 stars, based on 2219 article reviews
massarray system - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Sequencing:Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025). Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, Real-time Polymerase Chain Reaction:Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025). Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, Polymerase Chain Reaction:Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025). Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, Multiplex PCR:Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025). Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, Multiplex Assay:Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025). Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, Next-Generation Sequencing:Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025). Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, Concentration Assay:Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025). Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, Mass Spectrometry:Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025). Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, Amplification:Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025). Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, Protein-Protein interactions:Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025). Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, Functional Assay:Article Title: Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025). Article Snippet: echniques, including TaqMan allelic discrimination assays, polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), conventional PCR followed by Sanger sequencing, real-time PCR, |